{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T07:35:15Z","timestamp":1776065715837,"version":"3.50.1"},"reference-count":62,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jacadv.2025.101708","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T16:33:22Z","timestamp":1745685202000},"page":"101708","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Treatment of Homozygous Familial Hypercholesterolemia"],"prefix":"10.1016","volume":"4","author":[{"given":"Jaimini","family":"Cegla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahenaz","family":"Walji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"Barton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clare","family":"Neuwirth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilbert R.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacadv.2025.101708_bib1","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(75)92193-5","article-title":"Plasma exchange in the management of homozygous familial hypercholesterolaemia","volume":"1","author":"Thompson","year":"1975","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2025.101708_bib2","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1016\/S0021-9258(19)42341-7","article-title":"Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia","volume":"249","author":"Goldstein","year":"1974","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jacadv.2025.101708_bib3","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 update on European Atherosclerosis Society consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance","volume":"44","author":"Cuchel","year":"2023","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.jacadv.2025.101708_bib4","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1161\/ATV.0000000000000177","article-title":"Lipoprotein apheresis: utility, outcomes, and Implementation in clinical practice: a scientific statement from the American Heart Association","volume":"44","author":"Gianos","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacadv.2025.101708_bib5","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/0002-9343(64)90196-2","article-title":"The inheritance of essential familial hypercholesterolemia","volume":"37","author":"Khachadurian","year":"1964","journal-title":"Am J Med"},{"key":"10.1016\/j.jacadv.2025.101708_bib6","series-title":"Wellcome Witnesses to Twentieth Century Medicine","first-page":"xxi","article-title":"Plasma cholesterol as a cause of coronary heart disease (CHD); the cholesterol-CHD hypothesis","author":"Myant","year":"2006"},{"key":"10.1016\/j.jacadv.2025.101708_bib7","first-page":"1377","volume":"118","author":"de Gennes","year":"1967","journal-title":"Bull Mem Soc Med Hop Paris"},{"key":"10.1016\/j.jacadv.2025.101708_bib8","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1136\/bmj.291.6510.1671","article-title":"Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange","volume":"291","author":"Thompson","year":"1985","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.jacadv.2025.101708_bib9","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1515\/CCLM.2001.068","article-title":"The Friedewald formula underestimates LDL cholesterol at low concentrations","volume":"39","author":"Scharnagl","year":"2001","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jacadv.2025.101708_bib10","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0140-6736(81)91213-7","article-title":"Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia","volume":"2","author":"Stoffel","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2025.101708_bib11","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/0002-9149(92)90352-Y","article-title":"Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. The Liposorber Study Group","volume":"70","author":"Gordon","year":"1992","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacadv.2025.101708_bib12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/jca.20135","article-title":"Dextran-sulfate-adsorption of atherosclerotic lipoproteins from whole blood or separated plasma for lipid-apheresis--comparison of performance characteristics with DALI and Lipidfiltration","volume":"22","author":"Julius","year":"2007","journal-title":"J\u00a0Clin Apher"},{"key":"10.1016\/j.jacadv.2025.101708_bib13","first-page":"406","article-title":"Double filtration plasmapheresis","volume":"26","author":"Agishi","year":"1980","journal-title":"Trans Am Soc Artif Intern Organs"},{"key":"10.1016\/j.jacadv.2025.101708_bib14","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0009-3084(94)90152-X","article-title":"Heparin extracorporeal LDL precipitation (HELP): an effective apheresis procedure for lowering Lp(a) levels","volume":"67-68","author":"Armstrong","year":"1994","journal-title":"Chem Phys Lipids"},{"key":"10.1016\/j.jacadv.2025.101708_bib15","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1586\/14779072.6.5.629","article-title":"Comparison of different LDL apheresis methods","volume":"6","author":"Julius","year":"2008","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"9","key":"10.1016\/j.jacadv.2025.101708_bib16","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1161\/CIRCULATIONAHA.117.029435","article-title":"The low-density lipoprotein receptor genotype is a significant determinant of the rebound in low-density lipoprotein cholesterol concentration after lipoprotein apheresis among patients with homozygous familial hypercholesterolemia","volume":"136","author":"Drouin-Chartier","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.101708_bib17","doi-asserted-by":"crossref","DOI":"10.1194\/jlr.TR120001001","article-title":"FH through the retrospectoscope","volume":"62","author":"Thompson","year":"2021","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacadv.2025.101708_bib18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/1744-9987.13716","article-title":"The scientific basis and future of lipoprotein apheresis","volume":"26","author":"Thompson","year":"2022","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.jacadv.2025.101708_bib19","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.jacl.2011.04.001","article-title":"Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on familial hypercholesterolemia","volume":"5","author":"Ito","year":"2011","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacadv.2025.101708_bib20","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.numecd.2010.04.007","article-title":"The 2009 2nd Italian Consensus Conference on LDL-apheresis","volume":"20","author":"Stefanutti","year":"2010","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.jacadv.2025.101708_bib21","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.5551\/jat.14621","article-title":"Guidelines for the management of familial hypercholesterolemia","volume":"19","author":"Harada-Shiba","year":"2012","journal-title":"J\u00a0Atheroscler Thromb"},{"key":"10.1016\/j.jacadv.2025.101708_bib22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.atherosclerosis.2008.02.009","article-title":"Recommendations for the use of LDL apheresis","volume":"198","author":"Thompson","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacadv.2025.101708_bib23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1744-9987.2008.00574.x","article-title":"Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years","volume":"12","author":"Palcoux","year":"2008","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.jacadv.2025.101708_bib24","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.amjcard.2008.06.049","article-title":"Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia","volume":"102","author":"Hudgins","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacadv.2025.101708_bib25","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.amjcard.2008.07.035","article-title":"Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia","volume":"102","author":"Kolansky","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacadv.2025.101708_bib26","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jacl.2012.03.004","article-title":"Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia","volume":"6","author":"Gr\u00e6sdal","year":"2012","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacadv.2025.101708_bib27","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2025.101708_bib28","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.atherosclerosis.2016.10.017","article-title":"HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom","volume":"255","author":"France","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacadv.2025.101708_bib29","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41569-023-00892-0","article-title":"International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia","volume":"20","author":"Watts","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacadv.2025.101708_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.118601","article-title":"The German Lipoprotein Apheresis Registry-Summary of the eleventh annual report","volume":"398","author":"Schettler","year":"2024","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacadv.2025.101708_bib31","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1056\/NEJM199005243222104","article-title":"Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia","volume":"322","author":"Seed","year":"1990","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacadv.2025.101708_bib32","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/eurheartj\/ehx317","article-title":"Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol","volume":"39","author":"Thompson","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2025.101708_bib33","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.atherosclerosis.2017.01.015","article-title":"Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France","volume":"257","author":"Bruckert","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacadv.2025.101708_bib34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.athplu.2021.05.001","article-title":"Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: analysis on cytokines and lipid profile","volume":"43","author":"Lupo","year":"2021","journal-title":"Atheroscler Plus"},{"key":"10.1016\/j.jacadv.2025.101708_bib35","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0022-2275(20)41379-3","article-title":"The discovery and development of HMG-CoA reductase inhibitors","volume":"33","author":"Endo","year":"1992","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacadv.2025.101708_bib36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11883-002-0058-7","article-title":"Statins in homozygous familial hypercholesterolemia","volume":"4","author":"Marais","year":"2002","journal-title":"Curr Atheroscler Rep"},{"issue":"10","key":"10.1016\/j.jacadv.2025.101708_bib37","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/S0022-2275(20)37137-6","article-title":"Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia","volume":"38","author":"Marais","year":"1997","journal-title":"J\u00a0Lipid Res"},{"issue":"3","key":"10.1016\/j.jacadv.2025.101708_bib38","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0022-2275(20)37589-1","article-title":"Role of cholesterol in regulating apolipoprotein B secretion by the liver","volume":"37","author":"Thompson","year":"1996","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacadv.2025.101708_bib39","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","article-title":"Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy","volume":"124","author":"Raal","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.101708_bib40","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.0000018744.58460.62","article-title":"Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia","volume":"105","author":"Gagn\u00e9","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.101708_bib41","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/MOL.0b013e3281338531","article-title":"Unravelling the functional significance of PCSK9","volume":"18","author":"Lambert","year":"2007","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacadv.2025.101708_bib42","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrd3699","article-title":"The biology and therapeutic targeting of the proprotein convertases","volume":"11","author":"Seidah","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jacadv.2025.101708_bib43","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacadv.2025.101708_bib44","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S2213-8587(17)30044-X","article-title":"Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study","volume":"5","author":"Raal","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacadv.2025.101708_bib45","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacc.2020.05.027","article-title":"Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: the ODYSSEY HoFH trial","volume":"76","author":"Blom","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2025.101708_bib46","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","article-title":"The Agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association","volume":"132","author":"Gidding","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.101708_bib47","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2025.101708_bib48","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/CIRCULATIONAHA.118.034710","article-title":"Effect of an siRNA therapeutic targeting PCSK9 on atherogenic lipoproteins: prespecified secondary end points in ORION 1","volume":"138","author":"Ray","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.101708_bib49","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.122.063460","article-title":"Efficacy, safety, and tolerability of inclisiran in patients with homozygous familial hypercholesterolemia: results from the ORION-5 randomized clinical trial","volume":"149","author":"Raal","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.101708_bib50","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(21)02001-8","article-title":"Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study","volume":"399","author":"Tromp","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2025.101708_bib51","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia","volume":"356","author":"Cuchel","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacadv.2025.101708_bib52","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2025.101708_bib53","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/eurjpc\/zwab229","article-title":"Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study","volume":"29","author":"D'Erasmo","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacadv.2025.101708_bib54","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/liv.15497","article-title":"Long-term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia","volume":"43","author":"Larrey","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.jacadv.2025.101708_bib55","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jacl.2020.08.006","article-title":"Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER)","volume":"14","author":"Underberg","year":"2020","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacadv.2025.101708_bib56","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacadv.2025.101708_bib57","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1161\/ATVBAHA.123.320609","article-title":"Evinacumab and cardiovascular outcome in patients with homozygous familial hypercholesterolemia","volume":"44","author":"B\u00e9liard","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"10.1016\/j.jacadv.2025.101708_bib58","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1194\/jlr.RA120000888","article-title":"Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance","volume":"61","author":"Adam","year":"2020","journal-title":"J\u00a0Lipid Res"},{"issue":"3","key":"10.1016\/j.jacadv.2025.101708_bib59","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3390\/ijms26031026","article-title":"Novel RNA-based therapies in the management of dyslipidemias","volume":"26","author":"Kosmas","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacadv.2025.101708_bib60","article-title":"Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: the SAFEHEART follow-up study","volume":"393","author":"Alonso","year":"2024","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacadv.2025.101708_bib61","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/CIRCULATIONAHA.123.067957","article-title":"Established and emerging nucleic acid therapies for familial hypercholesterolemia","volume":"150","author":"Damase","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.101708_bib62","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","article-title":"In\u00a0vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates","volume":"593","author":"Musunuru","year":"2021","journal-title":"Nature"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25001255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25001255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T21:14:20Z","timestamp":1748466860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X25001255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2772963X25001255"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.101708","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Homozygous Familial Hypercholesterolemia","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.101708","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"101708"}}